Double-blind trial of thiothixene and chlorpromazine in acute schizophrenia.
In a double-blind trial of chlorpromazine and thiothixene conducted with 79 acutely ill, newly hospitalized schizophrenic patients, chlorpromazine and thiothixene were shown to be equally effective in producing meaningful symptomatic improvment over an average period of approximately 3 weeks, as measured by Global Assessments (CGI), BPRS, and NOSIE.
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D002746:Chlorpromazine / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011569:Psychiatric Status Rating Scales; D012559:Schizophrenia / Q000188:drug therapy*; D013888:Thiothixene / Q000009:adverse effects / Q000627:therapeutic use*
D013888:Thiothixene; D002746:Chlorpromazine